A short roundup of peptide research making the news this month. Each summary links to the original reporting so you can read the full story and the underlying study.
1. Catestatin shows multi-pathway effects in mouse models of neurodegeneration
September 22, 2026 · UC San Diego · published in Molecular Therapy
Researchers at UC San Diego studied catestatin (CST), a peptide the body produces naturally, in mouse models of neurodegeneration. In the animals, CST was associated with lower build-up of tau and amyloid proteins, reduced brain inflammation, and better performance on cognitive and motor tests. The team highlights that the peptide appeared to act on several disease-related pathways at once rather than a single target.
Keep in mind: this is preclinical work in mice. No human trials have been run, and safety and effectiveness in people are unknown. The researchers say more studies are needed first.
Read more: Yahoo News · UC San Diego Today
2. First patient dosed in a GRPR-targeted radiotherapy trial
September 8, 2026 · Alpha-9 Oncology
Alpha-9 Oncology has dosed the first patient in a Phase 1 trial of radiopharmaceuticals that target the gastrin-releasing peptide receptor (GRPR), a receptor found on breast cancer and several other solid tumors. The study is testing an actinium-based compound, 225Ac-A9-0642, described as the first of its kind to target GRPR in the clinic, alongside a lutetium-based compound, 177Lu-A9-0631. The trial will look at safety, tolerability and radiation dosimetry, and uses an imaging agent to select patients. The company expects data in late 2027.
Read more: Yahoo Finance
3. Medical-records study tracks rising BPC-157 use
September 15–16, 2026 · Reuters
Data analytics firm nference searched more than 15 million medical records and found 1,039 patients with documented BPC-157 use. Newly documented users rose about 33-fold between 2020 and 2026. Treatment responses were recorded for only about a third of patients, and the report notes 10 serious adverse-event reports to the FDA since 2021, eight of them in 2026.
Keep in mind: the study describes usage, not whether BPC-157 works or is safe. Experts quoted in the coverage stress that many patients were on other treatments at the same time and that randomized controlled trials are needed. BPC-157 is not an FDA-approved drug.
Read more: Yahoo News
This roundup summarizes third-party news for informational purposes only. It is not medical advice. All products sold by LuLu Peptides are for laboratory research use only and are not for human or veterinary use.
